Author

Y H Chen

Hong Kong University of Science and Technology

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:large language model· 1

Frequent Co-Authors

Bo Li· 1 shared Can YangiD· 1 shared Changhua ZhangiD· 1 shared Chu‐Xia DengiD· 1 shared Dongyang TangiD· 1 shared Fan Zhang· 1 shared Fangyuan ShaoiD· 1 shared Hao CheniD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bo Li

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

STAT: A multi-agent framework for integrated and interactive spatial transcriptomics analysis

Y H Chen, Shi Han, Zitong Chao, Yuyao Liu, Fan Zhang, Hao Chen, Jiguang Wang, Jiashun Xiao, Can Yang

STAT is a multi-agent framework that improves spatial transcriptomics analysis by enabling interactive, transparent, and efficient multi-task analysis across different data resolutions.

bioRxiv · May 7, 2026 · PreprintBioinformatics

A critical role of protein damage response in mediating cancer drug resistance

Fangyuan Shao, Jie Li, Hao Xiao, Ling Li, Bo Li, Y H Chen, Xiangpeng Chu, Maoxin Ran, Dongyang Tang, Yuzhong Peng, Yujian Huang, Lijian Wang, Yanxia Shi, Nan Shao, Kai Miao, , Chu‐Xia Deng

This study identifies protein damage response (PDR) as a key mechanism in cancer drug resistance, showing that targeting PDR components can enhance drug efficacy in resistant cells.

bioRxiv · Jul 17, 2024 · PreprintCancer Biology